FINWIRES · TerminalLIVE
FINWIRES

調査速報:Ual:好調な第1四半期決算は、2026年の燃料費見通しの下方修正によって相殺された。

By

-- 独立系調査会社CFRAは、に対し、以下の調査レポートを提供しました。CFRAのアナリストは、以下のように見解をまとめています。UALは、2026年第1四半期の調整後EPSが1.19ドル(前年同期比31%増)となり、市場予想の1.08ドルを上回りました。これは、総収益が146億ドル(前年同期比11%増)となり、市場予想の144億ドルを上回ったことが要因です。燃料費が3億6,000万ドル増加したにもかかわらず、営業利益率は4.2%(前年同期比35ベーシスポイント増)と堅調に推移しました。TRASM(座席マイル当たり収益)が前年同期比6.9%増の18.80セント、PRASM(座席マイル当たり収益)が前年同期比7.4%増の16.95セントとなったことから、同社の価格決定力の高さがうかがえます。 UALのプレミアム収益の流れが業績を支え、プレミアム収益は前年比14%増、ロイヤルティ収益は前年比13%増、ビジネス収益は前年比14%増となりました。同社は2026年の調整後EPSガイダンスを12.00~14.00ドルから7.00~11.00ドルに引き下げ、2026年の残りの期間でキャパシティを5パーセントポイント削減する計画です。経営陣は、段階的な収益回復アプローチにより、第2四半期に燃料費増加の40~50%、第3四半期に70~80%、第4四半期に85~100%を回収できると見込んでいます。第1四半期は、UALが長期的な成長軌道を維持しながら燃料費を転嫁できる能力があることを示す証拠となったと考えています。

Related Articles

Research

Morgan Stanley Downgrades AES to Equalweight From Overweight, Adjusts Price Target to $15 From $23

AES (AES) has an average rating of hold and mean price target of $15.12, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)

$AES
Australia

Compass Therapeutics Tovecimig Study Falls Short on Overall Survival Endpoint in Biliary Tract Cancer; Shares Fall Pre-Bell

Compass Therapeutics (CMPX) reported that its experimental drug tovecimig did not meet the overall survival secondary endpoint in a phase 2/3 study in patients with advanced biliary tract cancer, the company said Monday.Shares of the company fell more than 63% in recent pre-bell activity Monday.The company said that tovecimig plus paclitaxel did not show a statistically significant overall survival benefit versus chemotherapy alone, largely due to high crossover from the control arm and prolonged survival after switching to the drug.However, the study met other key endpoints, including statistically significant improvements in progression-free survival and overall response rate versus paclitaxel alone.Compass Therapeutics plans to meet with the US Food and Drug Administration to discuss the results ahead of a planned biologics license application submission, it added.Price: $1.91, Change: $-3.11, Percent Change: -63.35%

$CMPX
Sectors

Gold Eases Early Even as the Dollar Falls Ahead of This Week's U.S. Interest Rate Decision

Gold prices eased early on Monday, remaining rangebound even as the dollar fell ahead of the Wednesday interest-rate announcement from the Federal Reserve.Gold for June delivery was last seen down US$26.50 to US$4,714.40 per ounce, remaining within the US$200 range it has been stuck in since the start of the war on Iran, as high oil prices raise concerns over higher inflation and threaten to boost interest rates.The Federal Open Market Committee (FOMC) will make its latest interest-rate decision at the Wednesday afternoon end to its two-day meeting. The CME FedWatch Tool sees a 100% probability the group will leave rates unchanged."Gold remains stuck in neutral within a broad USD 200 range around USD 4,750, with most intraday price action dictated by energy prices and the ebb and flow of headlines from the White House and the Middle East. The FOMC is widely expected to leave rates unchanged on Wednesday," Saxo Bank noted.The dollar was lower early, with the ICE dollar index last seen down 0.28 points to 98.26. Treasury yields rose, with the yield on the two-year note up 1.0 basis points to 3.801%, while the 10-year note was paying 4.321%, up 1.3 points.

$GCM6$GLD